ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

additional imatinib (300 mg/m 2 ) daily.Patients who achieved remission by day 36 of therapy received consolidation chemotherapy according to the plan for intermediate-risk groups with low doses of MTX 30 mg /m 2 with lumbar punctures and continued treatment with imatinib until the end of maintenance therapy.More than half of the patients received induction courses of consolidation at an outpatient department.Discussion: Of 439 patients with ALL examined by immunophenotyping, and molecular genetic methods, t(9;22) BCR/ABL p190 was detected in 46 patients (10.4%).An early response was observed in 27 patients (60.1%) by day 15 of treatment.Death during remission was reported in 2 cases (4.3%).Forty-four patients achieved molecular remission after the induction course, regardless of the initial data and the response on day 15.Out of 46 patients who went into remission, death was reported in 3 cases (6.5%).The main cause of mortality was complications from infections of mixed bacterial-fungal etiology.Six patients relapsed, and 35 patients (76%±3%) achieved CCR.Conclusions: The use of tyrosine kinase inhibitors in combination with low-dose PCT showed high efficacy with a significant reduction in toxicity.This significantly improved the quality of life of patients and also led to a reduction in complications due to infectious.